Barclays analyst Julian Mitchell lowered the firm’s price target on Emerson (EMR) to $105 from $110 and keeps an Underweight rating on the shares. The firm adjusted targets in the multi-industry group as part of a Q1 preview. It sees revenue and margin pressure alongside lower investor expectations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: